- Global Pharma News & Resources

Coronavirus (COVID-19) Update: Daily Roundup

SILVER SPRING, Md., April 1, 2020 /PRNewswire/ -- The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:

  • FDA-ARGOS SARS-CoV-2 Reference Grade Sequence Data Now Available: In response to the COVID-19 pandemic, the FDA—in collaboration with the Centers for Disease Control and Prevention (CDC), the Biodefense and Emerging Infections Research Resources Repository (BEI Resources) and the Institute for Genome Sciences at the University of Maryland and the National Center for Biotechnology Information (NCBI)—developed quality-controlled, reference sequence data for the SARS-CoV-2 reference strain for the United States. Availability of traceable and quality-controlled data will help test developers and vaccine developers:
    • Expedite development of medical countermeasures.
    • Identify new or more stable targets for future tests.
    • Enable in silico confirmation of targets.
    • Support development of synthetic reference material.
    • Enable viral population/quasi species analysis.
  • The FDA issued a Constituent Update regarding guidance it released today to provide temporary flexibility to chain restaurants and similar retail food establishments currently required to provide nutrition information, including calories, on menus and menu boards.
  • The FDA is continuing to issue warning letters to companies for selling fraudulent COVID-19 products, as part of the agency's effort to protect consumers. FDA and FTC issued a warning letter to Neuro XPF, which sells cannabidiol (CBD) products in the U.S. with the misleading claim these products can mitigate, prevent, treat, diagnose, or cure COVID-19. The agency will continue to pursue those that place public health at risk.
  • Diagnostics update to date: During the COVID-19 pandemic, the FDA has worked with more than 220 test developers who have said they will be submitting emergency use authorizations (EUA) requests to FDA for tests that detect the virus. To date, 23 emergency use authorizations have been issued for diagnostic tests. On March 31st FDA issued an EUA that authorizes eligible molecular-based laboratory developed tests, or LDTs, that are developed and used by a single CLIA high complexity laboratory. Under this EUA, FDA has authorized Yale New Haven Hospital's SARS-CoV-2 PCR test. Additionally, the FDA has been notified that more than 110 laboratories have begun testing under the policies set forth in our COVID-19 Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Guidance. The FDA also continues to keep its COVID-19 Diagnostics FAQ up to date.

Additional Resources:

Media Contact: Brittney Manchester, 301-796-1026
Consumer Inquiries: 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.



View original content to download multimedia:

SOURCE U.S. Food and Drug Administration

Coronavirus (COVID-19) Update: Daily Roundup

Editor Details

Last Updated: 02-Apr-2020